Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
ARDS (acute respiratory distress syndrome)
COVID-19
JAK inhibitor
SARS-CoV-2
eculizumab
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
05
2020
accepted:
25
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of three weeks, or with the best available therapy (N = 10). Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.
Identifiants
pubmed: 32581810
doi: 10.3389/fphar.2020.00857
pmc: PMC7291857
doi:
Types de publication
Journal Article
Langues
eng
Pagination
857Informations de copyright
Copyright © 2020 Giudice, Pagliano, Vatrella, Masullo, Poto, Polverino, Gammaldi, Maglio, Sellitto, Vitale, Serio, Cuffa, Borrelli, Vecchione, Filippelli and Selleri.
Références
Pharmacol Res. 2020 Jul;157:104866
pubmed: 32387301
Blood. 2013 Dec 12;122(25):4047-53
pubmed: 24174625
Int Arch Allergy Immunol. 2020;181(6):467-475
pubmed: 32392562
J Virol. 2005 Jun;79(12):7819-26
pubmed: 15919935
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
Kidney Int Rep. 2019 Aug 02;4(11):1568-1576
pubmed: 31890998
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624
JAMA. 2020 Apr 13;:
pubmed: 32282022
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047
pubmed: 32329881
Clin Transl Sci. 2011 Oct;4(5):332-7
pubmed: 22029804
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
Haematologica. 2013 Dec;98(12):1865-71
pubmed: 24038026
Pediatr Allergy Immunol. 2020 May 2;:
pubmed: 32359201
J Clin Invest. 2011 Oct;121(10):3943-53
pubmed: 21926466
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760